Cocrystal PharmaCOCP
About: Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Employees: 12
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
43% more funds holding
Funds holding: 14 [Q2] → 20 (+6) [Q3]
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0.14% less ownership
Funds ownership: 7.21% [Q2] → 7.07% (-0.14%) [Q3]
26% less capital invested
Capital invested by funds: $1.71M [Q2] → $1.27M (-$444K) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for COCP.